Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5K8, Canada
Author to whom correspondence should be addressed.
Nutrients 2013, 5(3), 981-1001; https://doi.org/10.3390/nu5030981
Received: 22 January 2013 / Revised: 14 March 2013 / Accepted: 15 March 2013 / Published: 22 March 2013
(This article belongs to the Special Issue Dyslipidemia and Obesity)
Hypertriglyceridemia (HTG) is commonly encountered in lipid and cardiology clinics. Severe HTG warrants treatment because of the associated increased risk of acute pancreatitis. However, the need to treat, and the correct treatment approach for patients with mild to moderate HTG are issues for ongoing evaluation. In the past, it was felt that triglyceride does not directly contribute to development of atherosclerotic plaques. However, this view is evolving, especially for triglyceride-related fractions and variables measured in the non-fasting state. Our understanding of the etiology, genetics and classification of HTG states is also evolving. Previously, HTG was considered to be a dominant disorder associated with variation within a single gene. The old nomenclature includes the term “familial” in the names of several hyperlipoproteinemia (HLP) phenotypes that included HTG as part of their profile, including combined hyperlipidemia (HLP type 2B), dysbetalipoproteinemia (HLP type 3), simple HTG (HLP type 4) and mixed hyperlipidemia (HLP type 5). This old thinking has given way to the idea that genetic susceptibility to HTG results from cumulative effects of multiple genetic variants acting in concert. HTG most is often a “polygenic” or “multigenic” trait. However, a few rare autosomal recessive forms of severe HTG have been defined. Treatment depends on the overall clinical context, including severity of HTG, concomitant presence of other lipid disturbances, and the patient's global risk of cardiovascular disease. Therapeutic strategies include dietary counselling, lifestyle management, control of secondary factors, use of omega-3 preparations and selective use of pharmaceutical agents. View Full-Text
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Brahm, A.; Hegele, R.A. Hypertriglyceridemia. Nutrients 2013, 5, 981-1001.
AMA StyleShow more citation formats Show less citations formats
Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013; 5(3):981-1001.Chicago/Turabian Style
Brahm, Amanda; Hegele, Robert A. 2013. "Hypertriglyceridemia." Nutrients 5, no. 3: 981-1001.
Find Other Styles